mun.2018Mar5;9(1):948.[16]LiliangXia,YuanyongLiu,YingWang,etal.PD-1/PD-L1BlockadeTherapyinAdvancedNon-Small-CellLungCancer:CurrentStatusandFutureDirections[J].Oncologist.2019Feb;24(Suppl1):S31-S41.[17]Mu-YangHuang,Xiao-MingJiang,Bing-LinWang,etal.CombinationtherapywithPD-1/PD-L1blockadeinnon-smallcelllungcancer:strategiesandmechanisms[J].PharmacolTher.2021Mar;219:107694.[18]ChenD,BarsoumianHB,YangL,etal.SHP-2andPD-L1InhibitionCombinedwithRadiotherapyEn⁃hancesSystemicAntitumorEffectsinanAnti-PD-1-ResistantModelofNon-SmallCellLungCancer[J].CancerImmunolRes.2020Jul;8(7):883-894.[19]YuChen,MinGao,ZhaoqinHuang,etal.SBRTcom⁃binedwithPD-1/PD-L1inhibitorsinNSCLCtreat⁃ment:afocusonthemechanisms,advances,andfu⁃turechallenges[J].JHematolOncol.2020Jul28;13(1):105.[20]XianjingChu,LishuiNiu,GangXiao,etal.TheLong-TermandShort-TermEfficacyofImmunotherapyinNon-SmallCellLungCancerPatientsWithBrainMe⁃tastases:ASystematicReviewandMeta-Analysis[J].FrontImmunol.2022May25;13:875488.[21]HirenMandaliya,MarkJones,C...